Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026.

Rhea-AI Summary

Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.

Argus Feb 12 session

+1.49% close to close Open Argus

Details

News Market Reaction – ZYME

On Feb 12, the day this news came out, ZYME closed 1.49% above the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Market Context

This announcement set expectations for Zymeworks’ fourth quarter and full year 2025 results, schedul...

Analysis

This announcement set expectations for Zymeworks’ fourth quarter and full year 2025 results, scheduled for pre-market release on March 2, 2026, followed by an 8:30 am ET conference call. In recent months, the company has reported positive Phase 3 data and outlined eligibility for up to $440.0M in regulatory milestones, with cash of about $270.6M as of Dec 31, 2025. Investors may focus on how the upcoming results and guidance contextualize these prior milestones and the broader 2026 strategic outlook.

Key Figures

Earnings release date: March 2, 2026 Conference call time: 8:30 am ET

Earnings release date

March 2, 2026

Fourth quarter and full year 2025 financial results pre-market

Conference call time

8:30 am ET

Management call to discuss 2025 results and corporate update

Historical Context

5 past events · Latest: Jan 27

5 events

1. Jan 27

   Conference participation

   24h Move

   +1.5%

   Announced multiple investor conference appearances in Feb–Mar 2026.

2. Jan 12

   Leadership changes

   24h Move

   -0.0%

   Board and executive role changes to support updated corporate strategy.

3. Jan 11

   Strategy & outlook

   24h Move

   -0.0%

   Outlined 2026 strategy, Phase 3 success, milestones up to $440.0M and cash of $270.6M.

4. Jan 06

   Phase 3 results

   24h Move

   -5.1%

   Reported strong HERIZON-GEA-01 survival and PFS benefits for Ziihera combinations.

5. Dec 02

   Conference schedule

   24h Move

   +4.5%

   Announced ASCO GI and J.P. Morgan conference participation and presentation timings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biotherapeutics

1 terms

biotherapeutics medical

"developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced"

Biotherapeutics are medicines made from living cells or biological molecules—such as proteins, antibodies, vaccines, or engineered cells and genes—designed to prevent, treat, or cure disease by working with the body’s natural systems. They matter to investors because they can offer groundbreaking, high-value treatments but also come with higher development, manufacturing and regulatory complexity, so their commercial success can drive large stock moves like a breakthrough product or a failed trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET).

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Investor inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Zymeworks (ZYME) report Q4 and full year 2025 financial results?

Zymeworks will report Q4 and full year 2025 results pre-market on March 2, 2026. According to the company, management will release results before market open and follow with a call and webcast the same day.

What time is the Zymeworks (ZYME) conference call and webcast on March 2, 2026?

The conference call and webcast are scheduled for 8:30 am Eastern Time on March 2, 2026. According to the company, management will discuss financial results and provide a corporate update during the event.

How can investors access Zymeworks (ZYME) earnings conference call on March 2, 2026?

Investors can join the conference call and webcast provided by Zymeworks on March 2, 2026 at 8:30 am ET. According to the company, the webcast will be available via the company's investor relations channels on the scheduled date.

Will Zymeworks (ZYME) discuss corporate strategy during the March 2, 2026 call?

Yes. Management will discuss financial results and provide a corporate update during the March 2, 2026 call at 8:30 am ET. According to the company, the webcast will cover recent developments and outlook alongside the results.

Is Zymeworks (ZYME) releasing earnings before or after market open on March 2, 2026?

Zymeworks will release its Q4 and full year 2025 financial results pre-market on March 2, 2026. According to the company, the pre-market release precedes the 8:30 am ET conference call and webcast the same day.

What should shareholders expect from Zymeworks (ZYME) March 2, 2026 webcast?

Shareholders should expect a presentation of Q4 and full year 2025 financial results and a corporate update at the webcast. According to the company, management will review results and address business developments during the March 2, 2026 session.